🇮🇳 Biocon Ltd

Press Release 18-11-2026 08:33:41 IST

Overview: The European Commission granted marketing authorization for Pebrilzo®, a biosimilar pertuzumab for HER2-positive breast cancer, under the EMA's new tailored clinical approach.

Open document in a new tab

Get filings like this in Telegram the moment they are published — for the companies you follow.

Start 30-day trial About Finterest